Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,490 questions · 1,526 findings · 124 reviews

No studies found 263 · 17.2%GRADE not reported 224 · 14.7%Very low 292 · 19.1%Low 327 · 21.4%Moderate 286 · 18.7%High 134 · 8.8%

Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine)

Progression‐free survival · people with advanced gastric cancer

Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).

1 finding from 1 review

Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine)

Treatment‐related death · people with advanced gastric cancer

It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).

1 finding from 1 review

Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine)

Treatment discontinuation due to toxicity · people with advanced gastric cancer

It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of infants with HBV mother‐to‐child transmission · HIV‐positive pregnant women co‐infected with hepatitis B virus
1 finding from 1 review

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

1 finding from 1 review

IStent in combination with phacoemulsification vs phacoemulsification alone

Proportion of participants who were drop‐free · open‐angle glaucoma

It is very uncertain whether IStent in combination with phacoemulsification changes proportion of participants who were drop‐free compared with phacoemulsification alone (very low certainty).

1 finding from 1 review

A combination of individual‐level interventions vs no intervention/wait list/placebo/no stress‐reduction intervention

Stress symptoms ( · healthcare workers
3 findings from 1 review